METHODS FOR TREATING PANCREATIC CANCER USING COMBINATION THERAPY COMPRISING LIPOSOMAL IRINOTECAN Russian patent published in 2018 - IPC A61K9/00 A61K31/4745 A61K31/513 A61K31/517 A61P35/00 

FIELD: medicine.

SUBSTANCE: group of inventions relates to medicine and can be used to treat pancreatic cancer in a human patient. To this end, the patient is administered an effective amount of liposomal irinotecan, 5-fluorouracil (5-FU) and leucovorin. Method includes at least one cycle, wherein the cycle is a 2 week period. For each cycle, liposomal irinotecan is administered to patients not homozygous for the UGT1A1*28 allele, on day 1 of each cycle at a dose of 80 mg/m², and patients that are homozygous for the UGT1A1*28 allele, on day 1 of cycle 1 at a dose of 60 mg/m² and on day 1 of each subsequent cycle at a dose of 60 mg/m² or 80 mg/m². 5-Fluorouracil is administered at a dose of 2400 mg/m². Leucovorin is administered at a dose of 200 mg/m² (l-form) or 400 mg/m² (l+d-racemic form). Also disclosed is the use of the liposomal irinotecan composition, and a kit for treating pancreatic cancer in a human patient.

EFFECT: group of inventions provides treatment of pancreatic cancer in a human patient not homozygous or homozygous for the UGT1A1*28 allele.

23 cl, 9 tbl, 7 dwg, 7 ex